Kit for evaluating curative effect of platinum drugs for patients with lung cancer or bladder cancer and application of kit

A platinum-based drug and curative effect evaluation technology, applied in the field of molecular biology, can solve the problems of huge differences in the curative effect of platinum-based drugs, affecting the treatment effect, prognosis and quality of life of patients, and achieve rigorous detection, good specificity, and reduced operational errors Effect

Active Publication Date: 2022-04-12
润安医学科技(苏州)有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in the case of the same treatment plan and dosage, the efficacy of platinum-based drugs varies greatly among patients, which seriously affects the treatment effect, prognosis and quality of life of patients.
[0003] At present, there are no well-performed clinical markers and methods for evaluating the efficacy of platinum-based drugs in patients with lung cancer and bladder cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Kit for evaluating curative effect of platinum drugs for patients with lung cancer or bladder cancer and application of kit
  • Kit for evaluating curative effect of platinum drugs for patients with lung cancer or bladder cancer and application of kit
  • Kit for evaluating curative effect of platinum drugs for patients with lung cancer or bladder cancer and application of kit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] Example 1 Verify that the decreased expression of snoRNA SDORD33 leads to decreased sensitivity of lung cancer cells to cisplatin

[0046] First, four lung cancer cell lines A549, PC9, NCI-H1650, and H4006 were treated with different concentrations of cisplatin, and the snoRNA SNORD33 gene in these four lung cancer cell lines was knocked out. After 48 hours, the They were treated with different concentrations of cisplatin and tested by CCK-8 experiment. The results showed that after the snoRNA SNORD33 gene was knocked out, the expression of snoRNA SNORD33 in the four lung cancer cell lines was significantly reduced, the lethality of the cisplatin drug on the four lung cancer cell lines was significantly weakened, and the number of viable cells was significantly increased. The half-inhibitory concentration (IC50) was significantly increased ( figure 1 ), thus indicating that the downregulation of snoRNA SNORD33 expression is closely related to the sensitivity of lung ca...

Embodiment 2

[0047] Example 2 Verification that the decreased expression of snoRNA SDORD33 leads to decreased sensitivity of bladder cancer cells to cisplatin

[0048] Firstly, two bladder cancer cell lines J82 and TCCSUP were treated with different concentrations of cisplatin, and the snoRNA SNORD33 gene in these two bladder cancer cell lines were respectively knocked out. After 48 hours, different concentrations of cisplatin Cisplatin drugs were treated separately and tested by CCK-8 experiment. The results showed that after the snoRNA SNORD33 gene was knocked out, the expression levels of snoRNA SNORD33 in the two bladder cancer cell lines were significantly reduced, the lethality of cisplatin on the two bladder cancer cell lines was significantly weakened, and the number of viable cells was significantly increased. The half-inhibitory concentration (IC50) of platinum drugs was significantly increased ( figure 2 ), thus indicating that the downregulation of snoRNA SNORD33 expression i...

Embodiment 3

[0049] Example 3 Verify that there are significant differences in the expression of snoRNA SNORD33 in the plasma samples of lung cancer patients and bladder cancer patients with different curative effects on platinum-based drugs

[0050] After a lot of research, the inventor team found that there is a significant difference in the expression of snoRNA SNORD33 in the plasma samples of lung cancer patients and bladder cancer patients with different curative effects on platinum-based drugs, and snoRNA SNORD33 can be used as a marker for evaluating the efficacy of platinum-based drugs in patients with lung cancer and bladder cancer. molecular markers.

[0051] Plasma samples were collected from 57 lung cancer patients with good efficacy of platinum-based drugs and 62 lung cancer patients with poor efficacy of platinum-based drugs, plasma samples of 48 bladder cancer patients with good efficacy of platinum-based drugs and 59 patients with poor efficacy of platinum-based drugs. The ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Login to view more

Abstract

The invention relates to the technical field of molecular biology, and particularly discloses application of snoRNA SNORD33 in preparation of a kit and/or a preparation for evaluating curative effects of platinum drugs for patients with lung cancer or bladder cancer. Platinum drugs are common chemotherapeutic drugs for treating lung cancer and bladder cancer patients, however, the expression quantities of the snoRNA SNORD33 in the plasma of the patients are different, so that the curative effects of the patients on the platinum drugs are different, and therefore, the detection of the expression quantity difference of the snoRNA SNORD33 in the plasma can be used for evaluating the curative effects of the platinum drugs of the lung cancer or bladder cancer patients. The invention further provides a kit capable of detecting the expression quantity of the snoRNA SNORD33. The kit comprises a reverse transcription reaction system and a fluorescent quantitative PCR reaction system. The kit is rapid and convenient in detection and high in accuracy, and can realize platinum drug curative effect evaluation of patients with lung cancer or bladder cancer. The method can assist doctors in evaluating and judging the curative effect of platinum drugs for patients with lung cancer or bladder cancer, provides valuable decision basis and reference information for the doctors to select proper treatment schemes, is beneficial to improving the treatment effect and life quality of the patients with lung cancer or bladder cancer, and has very important clinical value.

Description

technical field [0001] The present invention relates to the technical field of molecular biology, in particular to the application of snoRNA SNORD33 in the preparation of platinum-based drug curative effect evaluation kits and / or preparations for lung cancer or bladder cancer patients, a platinum-based drug curative effect evaluation kit for lung cancer or bladder cancer patients and its application. Background technique [0002] Platinum is a classic DNA-damaging drug. After platinum-based drugs such as cisplatin or carboplatin enter tumor cells, they form Pt-DNA adducts, which cause cross-linking between DNA and DNA inside tumor cells, resulting in DNA structure damage. Impairment of replication, thereby inhibiting DNA replication and transcription, and inducing cell death. Currently, the standard first-line chemotherapy regimen for patients with lung and bladder cancer is still based on platinum-based drugs. However, in the case of the same treatment plan and dosage, th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886C12Q1/6851C12N15/11
CPCY02A50/30
Inventor 陈舌张思张宇清宣涛
Owner 润安医学科技(苏州)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap